Article authored and contributed to PharmaLeaders by: Carlo Chatman, Power PR Cell and gene therapies are dominating the world of drug development. With the promise of significant breakthroughs in treatment […]
Featured Article
The Importance of Pharma Marketers Engaging with the Nation’s Leading Prescribers
By Andrea
Contributed to PharmaLeaders by: Richard Zwickel, Chairman and CEO POCN Group Each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 cases […]
White Papers

Register for Webinar – 10 Hot Technologies Impacting Life Sciences Marketing
Brought to by PharmaLeaders & Presented by Collaborative Marketing Solutions Webinar: 10 Hot Technologies Impacting Life Sciences … FREE Download

Mental Health: An Insurance Industry Perspective
How payers look at priorities for care in a time of policy uncertainty and growing concerns in the patient advocacy community. No group of … FREE Download
Industry News
eXmoor pharma raises $35m to boost cell and gene therapy production
eXmoor pharma has received an investment of around $35m in its Series A round to support the expansion of its cell and gene therapy production capability. The fundraise saw the participation of new and existing investors Kineticos Ventures and MVM Partners, respectively. Kineticos … [Read More...]
Abiogen Pharma acquires 97.09% stake in EffRx Pharmaceuticals
Italy-based Abiogen Pharma has announced the acquisition of a 97.09% stake in Switzerland-based EffRx Pharmaceuticals. Abiogen Pharma’s business spans across many integrated aspects: research and development, manufacturing of pharmaceuticals under its own brand or third-party … [Read More...]
Marinus Pharmaceuticals gets positive opinion for ZTALMY from CHMP
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Marinus Pharmaceuticals’ ZTALMY (ganaxolone) oral suspension. This recommendation is for ZTALMY to serve as the adjunctive … [Read More...]
VarmX raises funds to seek IND approval for VMX-C001
Biotechnology company VarmX has raised an additional €30m in a Series B2 financing round to obtain investigational new drug (IND) approval for its lead compound VMX-C001. VMX-C001 is a modified recombinant human blood clotting factor X that enables patients taking direct oral … [Read More...]